Board of Directors

Dr Roger Aston

CHAIRMAN - B. Sc. (Hons), PhD.

Dr Aston has more than 20 years experience in the pharmaceutical and biotech industries. He was the founding Chief Executive Officer of Mayne Pharma Group Limited, after leading HalcyGen’s acquisition of Mayne Limited in 2009. He has extensive experience with FDA and EU product registration, clinical trials, global licensing, private placement fundraising and prospectus preparation. Dr Aston has held numerous other board positions in the sector including with Clinuvel Limited, HalyGen Limited and Ascent Pharma Health Limited, recently acquired by Watson. 

Peter Anastasiou

EXECUTIVE VICE CHAIRMAN - BBSc

Mr. Anastasiou has extensive business experience in a wide range of organisations.  He has been a successful entrepreneur from and early age with his first biotech venture, Neuro Developments Australia, seeded at age 24.  Mr. Anastasiou was the founder of Investment Group Grandlodge, and ACS International both of which have generated significant wealth through Investment and Management

Daniel Pollock

NON-EXECUTIVE DIRECTOR - LL.B. Dip.L.P.

Daniel Pollock is an internationally experienced lawyer with commercial expertise in new market entries into overseas markets, distribution agreements and corporate start-ups. Mr Pollock is the principle of a specialist legal business based in Melbourne, operating internationally. He is admitted in both Scotland and Australia. He has local and global business experience, and a strong understanding of rapidly growing, technology-based businesses. Mr Pollock has a long time involvement with international public corporations and corporate governance.

Stephen Anastasiou

NON-EXECUTIVE DIRECTOR - B.Sc.(Hons), Grad. Dip MK

Mr Anastasiou has extensive experience in general management, marketing and strategic planning in the healthcare industry. Formerly with KPMG, his breadth of industry experience incorporates diagnostics, ethical, hospital, dental and OTC products with local and international companies such as Bristol-Myers Squibb. He is a director and shareholder of a number of unlisted private companies covering a variety of industry sectors including healthcare and funds management.

Professor Ravi Savarirayan

NON-EXECUTIVE DIRECTOR

Appointed as a Non-Executive Director of the Company on April 1, 2017. He is a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as Professor and Research Group Leader (Skeletal Biology and Disease) at the Murdoch Children’s Research Institute since September 2000. Mr. Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium  since January 2011 and has been the Chair of the Specialist Advisory Committee in Clinical Genetics, Royal Australasian College of Physicians since February 2009 . He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several International Working Committees on Constitutional Diseases of Bone. Mr. Savarirayan’s primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 150 peer-reviewed articles, collaborating with peers from over 30 countries, and has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics since July 2007, American Journal of Medical Genetics since December 2011 and Journal of Medical Genetics since June 2005.  Mr. Savarirayan received his MBBS from the University of Adelaide in 1990 and became a fellow of the Royal Australasian College of Physicians in December 1997. He was certified as a specialist in clinical genetics from the Human Genetics Society of Australasia in 1998 and received his Doctor of Medicine from the University of Melbourne in 2004, for his thesis “Clinical and Molecular Studies in the Osteochondrodysplasias.”